🟢 EIQ.AX is trading 40% up today on FDA decision anticipation and Mayo Clinic collaboration

EIQ.AX is trading 40% up today at $1.74 as investors position ahead of an expected FDA decision on its heart-failure AI tool and respond to growing interest in its cardiology platform.

• Optimism is building around the EchoSolv HF 510(k) submission following strong validation data from the Mayo Clinic.
• An expanded collaboration with the Mayo Clinic for potential U.S. distribution is further reinforcing the outlook for future commercialization and regulatory clearance.